PL02.3.A NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM) Article

Lassman, AB, Polley, MC, Iwamoto, FM et al. (2023). PL02.3.A NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM) . NEURO-ONCOLOGY, 25(Supplement_2), ii2-ii2. 10.1093/neuonc/noad137.005

cited authors

  • Lassman, AB; Polley, MC; Iwamoto, FM; Sloan, AE; Wang, TJC; Aldape, KD; Wefel, JS; Gondi, V; Gutierrez, AN; Manasawala, M; Gilbert, MR; Sulman, EP; Wolchok, JD; Greene, RM; Neil, EC; Lukas, RV; Goldlust, SA; Snuderl, M; Dignam, JJ; Won, M; Movsas, B; Mehta, MP

authors

publication date

  • September 8, 2023

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • ii2

end page

  • ii2

volume

  • 25

issue

  • Supplement_2